These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 15023581)

  • 1. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease.
    Lewczuk P; Esselmann H; Groemer TW; Bibl M; Maler JM; Steinacker P; Otto M; Kornhuber J; Wiltfang J
    Biol Psychiatry; 2004 Mar; 55(5):524-30. PubMed ID: 15023581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
    Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
    Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry.
    Gelfanova V; Higgs RE; Dean RA; Holtzman DM; Farlow MR; Siemers ER; Boodhoo A; Qian YW; He X; Jin Z; Fisher DL; Cox KL; Hale JE
    Brief Funct Genomic Proteomic; 2007 Jun; 6(2):149-58. PubMed ID: 17584762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
    Portelius E; Zetterberg H; Andreasson U; Brinkmalm G; Andreasen N; Wallin A; Westman-Brinkmalm A; Blennow K
    Neurosci Lett; 2006 Dec; 409(3):215-9. PubMed ID: 17049739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods.
    Simonsen AH; Hansson SF; Ruetschi U; McGuire J; Podust VN; Davies HA; Mehta P; Waldemar G; Zetterberg H; Andreasen N; Wallin A; Blennow K
    Dement Geriatr Cogn Disord; 2007; 23(4):246-50. PubMed ID: 17310122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.
    Portelius E; Brinkmalm G; Tran AJ; Zetterberg H; Westman-Brinkmalm A; Blennow K
    Neurodegener Dis; 2009; 6(3):87-94. PubMed ID: 19229112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides.
    Bibl M; Esselmann H; Otto M; Lewczuk P; Cepek L; Rüther E; Kornhuber J; Wiltfang J
    Electrophoresis; 2004 Sep; 25(17):2912-8. PubMed ID: 15349929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
    Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.
    Lewczuk P; Esselmann H; Otto M; Maler JM; Henkel AW; Henkel MK; Eikenberg O; Antz C; Krause WR; Reulbach U; Kornhuber J; Wiltfang J
    Neurobiol Aging; 2004 Mar; 25(3):273-81. PubMed ID: 15123331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.
    Motter R; Vigo-Pelfrey C; Kholodenko D; Barbour R; Johnson-Wood K; Galasko D; Chang L; Miller B; Clark C; Green R
    Ann Neurol; 1995 Oct; 38(4):643-8. PubMed ID: 7574461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptides.
    Ghidoni R; Albertini V; Squitti R; Paterlini A; Bruno A; Bernardini S; Cassetta E; Rossini PM; Squitieri F; Benussi L; Binetti G
    J Alzheimers Dis; 2009; 18(2):295-303. PubMed ID: 19584443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.
    Wiltfang J; Esselmann H; Smirnov A; Bibl M; Cepek L; Steinacker P; Mollenhauer B; Buerger K; Hampel H; Paul S; Neumann M; Maler M; Zerr I; Kornhuber J; Kretzschmar HA; Poser S; Otto M
    Ann Neurol; 2003 Aug; 54(2):263-7. PubMed ID: 12891683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry.
    Portelius E; Westman-Brinkmalm A; Zetterberg H; Blennow K
    J Proteome Res; 2006 Apr; 5(4):1010-6. PubMed ID: 16602710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing.
    Lewczuk P; Kornhuber J; Vanmechelen E; Peters O; Heuser I; Maier W; Jessen F; Bürger K; Hampel H; Frölich L; Henn F; Falkai P; Rüther E; Jahn H; Luckhaus Ch; Perneczky R; Schmidtke K; Schröder J; Kessler H; Pantel J; Gertz HJ; Vanderstichele H; de Meyer G; Shapiro F; Wolf S; Bibl M; Wiltfang J
    Exp Neurol; 2010 Jun; 223(2):366-70. PubMed ID: 19664622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Abeta-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Toropygin IY; Kugaevskaya EV; Mirgorodskaya OA; Elisseeva YE; Kozmin YP; Popov IA; Nikolaev EN; Makarov AA; Kozin SA
    Rapid Commun Mass Spectrom; 2008; 22(2):231-9. PubMed ID: 18085519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?
    Schoonenboom NS; Mulder C; Van Kamp GJ; Mehta SP; Scheltens P; Blankenstein MA; Mehta PD
    Ann Neurol; 2005 Jul; 58(1):139-42. PubMed ID: 15984010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology.
    Maddalena AS; Papassotiropoulos A; Gonzalez-Agosti C; Signorell A; Hegi T; Pasch T; Nitsch RM; Hock C
    Neurodegener Dis; 2004; 1(4-5):231-5. PubMed ID: 16908995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.